Water Soluble Rhenium-based Complexes for Cancer Treatment
- Detailed Technology Description
- This invention relates to novel anti-cancer compoundsconsisting of rhenium which are (i) more potent than platinum-basedchemotherapeutic agents such as cisplatin and (ii) show anti-cancer activityagainst cisplatin-resistant cancer cells.
- Others
-
- PCT Application filed WO2017/223428
- Kevin M. Knopf,et al. (2017). In Vitro Anticancer Activity and in Vivo Biodistribution ofRhenium(I) Tricarbonyl Aqua Complexes. J. Am. Chem. Soc. 139 (40), pp14302–14314. DOI: 10.1021/jacs.7b08640.
- *Abstract
-
About half of treatedcancer patients receive platinum-based drugs (eg. cisplatin, carboplatin) aloneor in co-administration with other anticancer agents. Despite their efficacy, their use is limitedby toxic side effects and inherent or acquired resistance to platinum-baseddrugs by tumor cells.
The presentrhenium (I) complexes contain axial water ligands for enhanced water solubilityto enable better formulation. Inaddition, the lead complex shows increased potency both in non-resistant and cisplatin-resistanttumor cells.
Table 1. Anticancer activities in humancervical cancer cells (HeLa)
Table 2. Anticancer activities in Chemo-sensitiveand Chemo-resistant cancer cell lines
PotentialApplications
Treatmentof cisplatin-resistant tumors.
Advantages
- Effective anticancer activity in cisplatin-resistant and cisplatin-susceptiblecancer cell lines
- Water soluble complex
- Greater potency
- *Licensing
- Phillip Owhpo62@cornell.edu1-607-254-4508
- Country/Region
- USA
